NO301879B1 - Indol-derivater - Google Patents

Indol-derivater

Info

Publication number
NO301879B1
NO301879B1 NO943913A NO943913A NO301879B1 NO 301879 B1 NO301879 B1 NO 301879B1 NO 943913 A NO943913 A NO 943913A NO 943913 A NO943913 A NO 943913A NO 301879 B1 NO301879 B1 NO 301879B1
Authority
NO
Norway
Prior art keywords
indole derivatives
indole
derivatives
Prior art date
Application number
NO943913A
Other languages
English (en)
Norwegian (no)
Other versions
NO943913D0 (no
NO943913L (no
Inventor
Alfredo Cugola
Giovanni Gaviraghi
Simone Giacobbe
Original Assignee
Glaxo Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Spa filed Critical Glaxo Spa
Publication of NO943913D0 publication Critical patent/NO943913D0/no
Publication of NO943913L publication Critical patent/NO943913L/no
Publication of NO301879B1 publication Critical patent/NO301879B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
NO943913A 1992-04-16 1994-10-14 Indol-derivater NO301879B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929208492A GB9208492D0 (en) 1992-04-16 1992-04-16 Heterocyclic compounds
PCT/EP1993/000938 WO1993021153A1 (en) 1992-04-16 1993-04-15 Indole-2-carboxylic acid derivatives

Publications (3)

Publication Number Publication Date
NO943913D0 NO943913D0 (no) 1994-10-14
NO943913L NO943913L (no) 1994-12-14
NO301879B1 true NO301879B1 (no) 1997-12-22

Family

ID=10714220

Family Applications (1)

Application Number Title Priority Date Filing Date
NO943913A NO301879B1 (no) 1992-04-16 1994-10-14 Indol-derivater

Country Status (41)

Country Link
US (4) US5373018A (enExample)
EP (1) EP0568136A1 (enExample)
JP (2) JPH07505407A (enExample)
KR (1) KR100264114B1 (enExample)
CN (1) CN1042331C (enExample)
AP (1) AP480A (enExample)
AT (1) AT403917B (enExample)
AU (1) AU666927B2 (enExample)
BE (1) BE1006343A5 (enExample)
BG (1) BG62136B1 (enExample)
BR (1) BR1100323A (enExample)
CA (3) CA2094073A1 (enExample)
CH (1) CH685630A5 (enExample)
CY (1) CY2038B1 (enExample)
CZ (1) CZ285799B6 (enExample)
DK (1) DK169890B1 (enExample)
ES (1) ES2105924B1 (enExample)
FI (1) FI106198B (enExample)
FR (1) FR2690919B1 (enExample)
GB (2) GB9208492D0 (enExample)
GE (1) GEP19991704B (enExample)
GR (1) GR1001619B (enExample)
HK (1) HK95797A (enExample)
HU (2) HU217964B (enExample)
IL (1) IL105412A (enExample)
IS (1) IS3994A (enExample)
IT (1) IT1265325B1 (enExample)
LU (1) LU88248A1 (enExample)
MX (1) MX9302195A (enExample)
MY (1) MY112232A (enExample)
NO (1) NO301879B1 (enExample)
NZ (1) NZ247413A (enExample)
OA (1) OA10103A (enExample)
PL (1) PL176451B1 (enExample)
RO (1) RO113242B1 (enExample)
RU (1) RU2129544C1 (enExample)
SE (1) SE504336C2 (enExample)
SK (1) SK281941B6 (enExample)
TW (1) TW224457B (enExample)
WO (1) WO1993021153A1 (enExample)
ZA (1) ZA932642B (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9304500D0 (en) * 1993-03-05 1993-04-21 Glaxo Spa Heterocyclic compounds
US5519048A (en) * 1993-05-27 1996-05-21 Merrell Pharmaceuticals Inc. 3-(indol-3-yl)-propenoic acid derivatives and pharmaceutical compositions thereof
DK0701551T3 (da) * 1993-05-27 1997-10-20 Merrell Pharma Inc 3-(Indol-3-yl)propensyrederivater som NMDA-antagonister
GB9319243D0 (en) * 1993-09-17 1993-11-03 Glaxo Spa Heterocyclic compounds
GB9321221D0 (en) * 1993-10-14 1993-12-01 Glaxo Spa Heterocyclic compounds
TW280819B (enExample) * 1993-11-17 1996-07-11 Sumitomo Pharma
US5563157B1 (en) * 1994-10-31 1999-02-02 Hoecst Marion Roussel Inc Heterocycle substituted propenoic acid derivatives and pharmaceutical compositions thereof
GB9502695D0 (en) * 1995-02-11 1995-03-29 Glaxo Spa Pharmaceutical composition
GB9504361D0 (en) * 1995-03-04 1995-04-26 Glaxo Spa Heterocyclic compounds
US6030968A (en) * 1996-09-17 2000-02-29 The Regents Of The University Of California Positive AMPA receptor modulation to enhance brain neurotrophic factor expression
WO1998014427A1 (en) * 1996-09-30 1998-04-09 Hoechst Marion Roussel, Inc. Nmda (n-methyl-d-aspartate) antagonists
US5922752A (en) * 1997-06-11 1999-07-13 Hoechst Marion Roussell, Inc. NMDA (n-methyl-d-aspartate) antagonists
KR100440553B1 (ko) * 1998-03-26 2004-07-15 후지사와 야꾸힝 고교 가부시키가이샤 서방성 제제
KR100829297B1 (ko) * 2000-07-31 2008-05-13 다이닛본 스미토모 세이야꾸 가부시끼가이샤 2-아릴-8-옥소디히드로푸린 유도체를 유효성분으로 하는치매증 치료제
WO2003039540A2 (en) * 2001-11-09 2003-05-15 Sepracor Inc. D-amino acid oxidase inhibitors for learning and memory
AU2002364549B2 (en) * 2001-12-10 2007-11-22 Amgen, Inc Vanilloid receptor ligands and their use in treatments
PA8579701A1 (es) * 2002-08-23 2005-05-24 Pfizer Prod Inc Profarmaco inhibidor de beta-lactamasa
DE10306202A1 (de) 2003-02-13 2004-08-26 Grünenthal GmbH Arzneimittel enthaltend substituierte 2-Aryl-Aminoessigsäure-Verbindungen und/oder substituierte 2-Heteroaryl-Aminoessigsäure-Verbindungen
JP2006526612A (ja) * 2003-06-05 2006-11-24 ファイザー・プロダクツ・インク ベータ−ラクタマーゼ阻害剤・プロドラッグ
RU2247563C1 (ru) * 2003-06-16 2005-03-10 Пятигорская государственная фармацевтическая академия Способ получения твердой лекарственной формы, содержащей глюкозамина гидрохлорид
EP1689721B1 (en) * 2003-11-26 2010-07-14 Pfizer Products Inc. Aminopyrazole derivatives as gsk-3 inhibitors
RU2361862C2 (ru) * 2003-12-29 2009-07-20 Сепракор Инк. Пиррольные и пиразольные ингибиторы daao
RU2281755C2 (ru) * 2004-04-19 2006-08-20 Пятигорская государственная фармацевтическая академия Композиция - лекарственная форма противоартрозного средства глюкозамина гидрохлорида для ректального применения
US20060002999A1 (en) * 2004-06-17 2006-01-05 Forest Laboratories, Inc. Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
WO2007006003A2 (en) 2005-07-06 2007-01-11 Sepracor Inc. Combinations of eszopiclone and trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-n-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders
BRPI0706365A2 (pt) 2006-01-06 2011-03-22 Sepracor Inc Cicloalquilaminas como inibidores da recaptação de monoamina
US8053603B2 (en) 2006-01-06 2011-11-08 Sunovion Pharmaceuticals Inc. Tetralone-based monoamine reuptake inhibitors
EP2816024B8 (en) 2006-03-31 2018-04-04 Sunovion Pharmaceuticals Inc. Chiral amines
US7579370B2 (en) * 2006-06-30 2009-08-25 Sepracor Inc. Fused heterocycles
US7884124B2 (en) * 2006-06-30 2011-02-08 Sepracor Inc. Fluoro-substituted inhibitors of D-amino acid oxidase
US20080082066A1 (en) * 2006-10-02 2008-04-03 Weyerhaeuser Co. Crosslinked carboxyalkyl cellulose fibers having non-permanent and temporary crosslinks
EP1942104A1 (en) 2006-12-20 2008-07-09 sanofi-aventis Heteroarylcyclopropanecarboxamides and their use as pharmaceuticals
EP2074092A2 (en) * 2007-01-18 2009-07-01 Sepracor Inc. Inhibitors of d-amino acid oxidase
US7902252B2 (en) * 2007-01-18 2011-03-08 Sepracor, Inc. Inhibitors of D-amino acid oxidase
CA2688493C (en) 2007-05-31 2016-04-19 Sepracor Inc. Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors
US20090247644A1 (en) * 2008-03-28 2009-10-01 Forest Laboratories Holdings Limited Memantine formulations
WO2010017418A1 (en) * 2008-08-07 2010-02-11 Sepracor Inc. Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase
WO2010104093A1 (ja) 2009-03-10 2010-09-16 参天製薬株式会社 ４，６－ジクロロ－１ｈ－インドール－２－カルボン酸誘導体又はその塩を有効成分として含有する視神経障害の予防又は治療剤
US20110034434A1 (en) * 2009-08-07 2011-02-10 Sepracor Inc. Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
KR20160147868A (ko) 2014-04-30 2016-12-23 위펑 제인 쳉 D-아미노산 옥시다제 억제제로서 공지된 화합물의 용도
US11370775B2 (en) 2016-09-14 2022-06-28 Yufeng Jane Tseng Substituted benzimidazole derivatives as D-amino acid oxidase (DAAO) inhibitors
JP7305560B2 (ja) 2017-06-12 2023-07-10 グリテック， エルエルシー Ｎｍｄａアンタゴニスト及びｄ２／５ｈｔ２ａ又は選択的５ｈｔ２ａアンタゴニストによるうつ病の治療
CN112707874A (zh) * 2020-12-29 2021-04-27 广东中科药物研究有限公司 一种抗病毒化合物及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3010971A (en) * 1960-08-04 1961-11-28 Smith Kline French Lab Cyclopropylamine derivatives and processes for their preparation
DK500285A (da) * 1984-11-02 1986-05-03 Glaxo Group Ltd Cephalosporinantibiotika
US4960786A (en) * 1989-04-24 1990-10-02 Merrell Dow Pharmaceuticals Inc. Excitatory amino acid antagonists
JPH0347123A (ja) * 1989-05-05 1991-02-28 G D Searle & Co インドール―２―カルボキシレート化合物類を含有するｃｎｓ疾患治療用組成物
JP3058688B2 (ja) * 1990-07-16 2000-07-04 メレルダウファーマスーティカルズ インコーポレイテッド 興奮性アミノ酸拮抗剤
US5284862A (en) * 1991-03-18 1994-02-08 Warner-Lambert Company Derivatives of 2-carboxyindoles having pharmaceutical activity
US5145845A (en) * 1991-05-14 1992-09-08 Warner-Lambert Co. Substituted 2-carboxylindoles having pharmaceutical activity

Also Published As

Publication number Publication date
BG99111A (bg) 1995-05-31
EP0568136A1 (en) 1993-11-03
GB9208492D0 (en) 1992-06-03
HK95797A (en) 1997-08-08
LU88248A1 (fr) 1994-03-01
GB2266091A (en) 1993-10-20
MY112232A (en) 2001-05-31
NZ247413A (en) 1995-12-21
HU9402975D0 (en) 1995-02-28
GR1001619B (el) 1994-07-29
FI944800L (fi) 1994-10-12
ZA932642B (en) 1994-01-10
RU2129544C1 (ru) 1999-04-27
IS3994A (is) 1993-10-17
CZ254394A3 (en) 1995-07-12
ITRM930236A0 (it) 1993-04-15
BG62136B1 (bg) 1999-03-31
US5373018A (en) 1994-12-13
US5510367A (en) 1996-04-23
CN1042331C (zh) 1999-03-03
CA2094075A1 (en) 1993-10-17
DK169890B1 (da) 1995-03-27
BR1100323A (pt) 2000-06-27
SK124194A3 (en) 1995-05-10
FR2690919A1 (fr) 1993-11-12
PL176451B1 (pl) 1999-05-31
CN1085212A (zh) 1994-04-13
SE9301241L (sv) 1993-10-17
ES2105924B1 (es) 1998-07-01
US5374648A (en) 1994-12-20
KR100264114B1 (ko) 2000-11-01
CZ285799B6 (cs) 1999-11-17
CA2094076A1 (en) 1993-10-17
HU211826A9 (en) 1995-12-28
JPH07505407A (ja) 1995-06-15
CY2038B1 (en) 1998-04-30
RO113242B1 (ro) 1998-05-29
AU3692393A (en) 1993-10-21
DK43193D0 (da) 1993-04-15
NO943913D0 (no) 1994-10-14
BE1006343A5 (fr) 1994-07-26
GB9307808D0 (en) 1993-06-02
ES2105924A1 (es) 1997-10-16
ITRM930236A1 (it) 1994-10-15
US5374649A (en) 1994-12-20
TW224457B (enExample) 1994-06-01
OA10103A (en) 1996-12-18
NO943913L (no) 1994-12-14
CA2094073A1 (en) 1993-10-17
JPH0649027A (ja) 1994-02-22
SE504336C2 (sv) 1997-01-13
FI106198B (fi) 2000-12-15
IL105412A0 (en) 1993-08-18
AP480A (en) 1996-03-22
HU217964B (hu) 2000-05-28
GB2266091B (en) 1995-08-09
SK281941B6 (sk) 2001-09-11
FR2690919B1 (fr) 1995-05-05
AT403917B (de) 1998-06-25
DK43193A (da) 1993-10-17
GEP19991704B (en) 1999-08-05
ATA75293A (de) 1997-11-15
WO1993021153A1 (en) 1993-10-28
HUT70526A (en) 1995-10-30
AP9300524A0 (en) 1993-04-30
IT1265325B1 (it) 1996-10-31
AU666927B2 (en) 1996-02-29
FI944800A0 (fi) 1994-10-12
IL105412A (en) 1998-02-22
SE9301241D0 (sv) 1993-04-15
CH685630A5 (fr) 1995-08-31
MX9302195A (es) 1994-03-31
RU94045915A (ru) 1996-09-10

Similar Documents

Publication Publication Date Title
DK43193A (da) Indolderivater
FI944969A7 (fi) Indolijohdannaisia
FI942395A7 (fi) Indolijohdannaiset
FI933551A7 (fi) 5-heteroyyli-indolijohdannaisia
FI930208L (fi) Kinazolinderivat
FI935431A7 (fi) Kiantsoliinijohdannaisia
FI980341L (fi) 2-oksi-indolijohdannaisia
FI20002505L (fi) 5-aryyli-indolijohdannaisia
FI933037A7 (fi) Tiazolylvinylfenylderivat
FI920480A7 (fi) Indolijohdannainen
FI931558A7 (fi) Indolin johdannaisia
FI941423A7 (fi) 17beta-substituoidut 4-atsa-5alfa-androstan-3-onijohdannaiset
FI944805A7 (fi) Indolijohdannaisia 5-HT1-kaltaisina agonisteina
NO961475L (no) Indol-derivater
FI933697A7 (fi) 3-Piperidinyylimetyylikarboksylaattisubstituoidut indolit
DE69330497D1 (de) Chinazolin-derivate
DK0411150T3 (da) Indolderivater
DE69212058D1 (de) Indol-Derivate
FI20010214L (fi) Asyyliaminoindolijohdannaisia
DE59308714D1 (de) Cyclobutan-benzol-derivate
FI20002460L (fi) 4-difenyylimetyylipiperidiinijohdannaisia
FI940311A0 (fi) Indoleja
FI925774A7 (fi) Indolijohdannaiset
NO952288D0 (no) Benzazepinon-derivater
DE69313890D1 (de) 5-Aminoflavon-Derivate

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees

Free format text: LAPSED IN OCTOBER 2002